Key result
Concomitant aspirin links to ~2.8-fold higher major bleeding during clopidogrel therapy.
Why the study?
Clinicians must balance clopidogrel's clinical effectiveness with bleeding risk, but many previous studies have evaluated beneficial and adverse factors separately.
What clinical, comorbidity, and genetic risk factors are associated with major bleeding, any bleeding, and clinical ineffectiveness in patients receiving maintenance clopidogrel therapy?
Meta-Analysis
What clinical, comorbidity, and genetic risk factors are associated with major bleeding, any bleeding, and clinical ineffectiveness in patients receiving maintenance clopidogrel therapy?
This comprehensive meta-analysis of 52 RCTs establishes that concomitant aspirin and therapy >6 months significantly increase major bleeding on maintenance clopidogrel without improving efficacy, whereas renal dysfunction is the primary definite risk factor for clinical treatment failure.
Answers are grounded in this paper and cite their sources.
Avoid aspirin co-use and clopidogrel beyond 6 months to curb bleeding; extends renal function-guided risk stratification for maintenance therapy.
Although clopidogrel is a frequently used antiplatelet medication to treat and prevent atherothrombotic disease, clinicians must balance its clinical effectiveness with the potential side effect of bleeding. However, many previous studies have evaluated beneficial and adverse factors separately. The objective of our study was to perform a comprehensive meta-analysis of studies of clopidogrel's clinical effectiveness and/or risk of bleeding in order to identify and assess all reported risk factors, thus helping clinicians to balance patient safety with drug efficacy. We analyzed randomized controlled trials (RCTs) of maintenance use in four stages: search for relevant primary articles; abstract and full article screening; quality assessment and data extraction; and synthesis and data analysis. Screening of 7,109 articles yielded 52 RCTs that met the inclusion criteria. Twenty-seven risk factors were identified. "Definite risk factors" were defined as those with aggregated odds ratios (ORs) > 1 and confidence intervals (CIs) > 1 if analyzed in more than one study. Definite risk factors for major bleeding were concomitant aspirin use (OR 2.83, 95% CI 2.04-3.94) and long duration of clopidogrel therapy (> 6 months) (OR 1.74, 95% CI 1.21-2.50). Dual antiplatelet therapy, extended clopidogrel therapy, and high maintenance dose (150 mg/day) of clopidogrel were definite risk factors for any bleeding. Reduced renal function, both mild and severe, was the only definite risk factor for clinical ineffectiveness. These findings can help clinicians predict the risks and effectiveness of clopidogrel use for their patients and be used in clinical decision support tools.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2020) conducted a meta-analysis in Atherothrombotic disease treated with maintenance clopidogrel therapy. Concomitant aspirin use with maintenance clopidogrel therapy (and 26 other clinical, comorbidity, and genetic risk factors) vs. Clopidogrel monotherapy (or absence of the specific risk factor) was evaluated on Major bleeding (concomitant aspirin use vs clopidogrel alone) (OR 2.83, 95% CI 2.04-3.94). Concomitant aspirin use and therapy >6 months increased major bleeding with clopidogrel, while reduced renal function increased clinical ineffectiveness.
Synapse has enriched 10 related papers. Consider them for comparative context: